Abstract:Background: The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) predicts the risk of malignancy for the different categories of the ultrasound-guided fine-needle aspiration biopsy (FNAB). The objective of this study is to investigate the efficiencies of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutation test and the TBSRTC categories in distinguishing between benign and malignant thyroid nodules. Methods: In this study, 362 ultrasound-guided fine-needle aspiration (FNA) samples from 344 patients aged from 17 to 76 years old were retrospectively reviewed. The patients were classified into six groups (I-VI) according to the TBSRTC system. The amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) was used to evaluate the BRAF V600E mutation level in total 362 samples. Among of the 344 patients, 128 patients (131 thyroid nodules) who underwent surgeries were followed by histopathological examination. The predictive values of the BRAF V600E mutation test and TBSRTC categories were evaluated in these 131 thyroid nodules. Results: The median ages of the patients in the TBSRTC IV-VI group were smaller than those in the TBSRTC I-III groups. The proportion of nodules over 1 cm was larger than it in the TBSRTC IV group compared to the other groups. Significant differences in BRAF V600E mutation were observed (P < .001) among these six groups. The sensitivity (89.57%) for the detection of malignant thyroid nodules, negative predictive value (NPV; 45.45%) for the detection of benign nodules, and accuracy (86.26%) for distinguishing between benign and malignant thyroid nodules increased by combining the BRAF V600E mutation test and TBSRTC system when compared with the BRAF V600E mutation test and TBSRTC system respectively. The BRAF V600E mutation test alone demonstrated the increased positive predictive value (PPV; 98.91%) and specificity (93.75%) for the detection of malignant thyroid nodules compared to the TBSRTC method (alone or in combination with the BRAF V600E method). Conclusion: In summary, significant differences in age, nodule diameter, and BRAF V600E mutation were noted among the six categories of the TBSRTC system. The combination of the BRAF V600E mutation test and TBSRTC system demonstrated increases in the NPV, sensitivity, and accuracy, while the BRAF V600E method proved superiority to the TBSRTC system with regard to the PPV and specificity.

Relationship between BRAF V600E mutation, cervical lymph node metastases and extrathyroidal ;extension in papillary thyroid carcinoma

Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer with BRAF V600E Mutation.

Associations of the BRAF V600E Mutation with Sonographic Features in Patients with Papillary Thyroid Carcinoma

Identification of Specific Long Non-Coding RNA Expression: Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer

[Diagnostic Values of BRAF(V600E) Mutation Analysis and Bethesda System for Reporting Thyroid Cytopathology in Thyroid Nodules with TIRADS 4 and 5].

Use of the BRAF V600E Mutation in Fine-Needle Aspirations of Thyroid Nodules

The Features of Contrast Enhanced Ultrasound and BRAF V600E in Papillary Thyroid Carcinoma.

Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma

Value of Share Wave Elastography Combined with BRAFV600E in Predicting Central Lymph Nodes Metastasis of Papillary Thyroid Carcinoma

Integrating BRAFV600E mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma

Relationship between BRAF V600E mutation and clinicopathological features of papillary thyroid carcinoma patients combined with chronic lymphocytic thyroiditis

Prediction of Cervical Lymph Node Metastasis with Contrast-Enhanced Ultrasound and Association Between Presence of BRAFV600E and Extrathyroidal Extension in Papillary Thyroid Carcinoma

Correlation between clinicopathologic features and BRAF V600E gene mutation abundance in papillary thyroid carcinoma

BRAF V600E Mutation and the Bethesda System for Reporting Thyroid Cytopathology of Fine-Needle Aspiration Biopsy for Distinguishing Benign from Malignant Thyroid Nodules

The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients

BRAFV600E mutation and NIS expression in papillary thyroid carcinomas

BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma

[Clinical Role of BRAF V600E Mutation Testing in Thyroid Nodules].

Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients

[Invasive Properties of Papillary Thyroid Cancer with Concurrent BRAF(V600E) Mutation and Rearranged During Transfection Proto-Oncogene Protein Expression].

BRAFV600E mutation is not a positive predictor for distant metastasis in sporadic papillary thyroid carcinoma